Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease.

Abstract

This article describes our experience in the clinical use of nebulized opioids for the management of dyspnoea in patients with terminal cancer by reviewing three specific patient case studies in which this treatment was found to be both safe and effective in controlling breathlessness. The patients were treated with morphine, hydromorphone or anileridine in various doses according to their prior use of opioids. Additional formal studies are being initiated at this Centre.

• Authors: M Farncombe, S Chater
• Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 2 Issue 3 Pg. 184-7 (May 1994) ISSN: 0941-4355 [Print] Germany
• PMID: 7518312 (Publication Type: Case Reports, Journal Article)

Chemical References

• Isonipecotic Acids
• anileridine
• Morphine
• Hydromorphone

Topics

• Administration, Inhalation
• Aged
• Aged, 80 and over
• Bone Neoplasms (secondary)
• Dyspnea (drug therapy, etiology)
• Female
• Humans
• Hydromorphone (administration & dosage, therapeutic use)
• Isonipecotic Acids (administration & dosage, therapeutic use)
• Lung Diseases, Obstructive (drug therapy)
• Lung Neoplasms (complications, secondary)
• Male
• Middle Aged
• Morphine (administration & dosage, therapeutic use)
• Nebulizers and Vaporizers
• Pleural Effusion (complications)